Developer docs
API playgroundTry for free, no card

Search company profiles

AllMeD Solutions

Full company profile

uuid000kh1e

Namestring
AllMeD Solutions
Legal namestring
AllMeD Solutions Ltd.
Company typeenum
Public
Founded yearint
2001
Descriptiontext

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli publicly-traded medical device company founded in 2001 and headquartered in Or-Aqiva. The company develops, manufactures, and markets minimally invasive medical products internationally, sold directly to hospitals and healthcare institutions for use by physicians treating cardiovascular and urological conditions. Following the 2026 divestitures of Allium Stents (urological stents, sold to Dahlhausen, Germany) and Gardia Medical (embolic protection, sold to Abbott via Cardiovascular Systems, Inc.), the operating business is concentrated on the True Leaf subsidiary's mitral valve regurgitation program — a novel valve-in-docking-station architecture developed toward a first-in-human needle-stick heart valve replacement procedure — together with the retained ProCatid (formerly WIRION) distal embolic protection system, an independent filter unit deliverable on any commercially marketed guide wire. The company is funded through small public-market private placements (TASE), an Israel Innovation Authority R&D grant, and continues to advance TruLeaf through Phase I and II human clinical trials with Ethics Committee approvals in Israel and South Africa. It generates revenue predominantly through hardware sales of medical devices, though no current revenue figure is publicly disclosed in the input data.

Short descriptiontext

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli medical device company developing minimally invasive cardiovascular and embolic protection products, with its core subsidiary True Leaf advancing a mitral valve regurgitation treatment through clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive medical devices, cardiovascular intervention devices, mitral valve repair systems, embolic protection systems, urological stents
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Minimally Invasive Medical Devices
No data
Revenue model1 record
1Medical Device Manufacturing and Sales
TypeHardware Sales
Description

AllMeD Solutions Ltd develops, manufactures and markets minimally invasive medical products internationally. Products are used by physicians to treat a wide range of diseases and patients worldwide.

allmed-solutions.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1True Leaf
Description

Division developing solutions for mitral valve regurgitation treatment

allmed-solutions.com
+1 more record
Core offering1 text field

AllMeD Solutions Ltd. (TASE: ALMD) develops, manufactures, and markets minimally invasive medical products internationally. Its current portfolio centers on the TruLeaf division's mitral valve docking system for valve-in-docking-station implantation (in clinical trials) and the ProCatid distal embolic protection system — an independent filter unit compatible with any commercially marketed guide wire. Previously owned divisions Allium Stents (urological stents) and Gardia Medical (embolic protection devices) have been divested.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Rapid clinical improvements observed in patients with severe heart failure caused by valve issues following needle-stick procedure
Product overview1 text field

AllMeD Solutions Ltd. is a publicly traded company (TASE: ALMD) that develops, manufactures and markets minimally invasive medical products internationally. The company's portfolio includes its core subsidiary TruLeaf, which focuses on mitral valve regurgitation solutions with a docking system for valve replacement, and the ProCatid System, a distal embolic protection system. Previously sold subsidiaries include Allium Stents (urological stents) and Gardia Medical (embolic protection devices). The company invests in minimally invasive interventions that improve patient recovery processes.

Product and service3 records
1TruLeaf Mitral Valve Docking System
CategoryStructural heart / mitral valve repair device
Description

A minimally invasive mitral valve regurgitation solution consisting of a docking system that supports valve-in-docking-station implantation. Developed for patients with mitral valve regurgitation affecting millions of people worldwide. Phase I and Phase II human implantations have been performed by the True Leaf division.

2ProCatid Distal Embolic Protection System
CategoryEmbolic protection device
Description

A distal embolic protection system (formerly known as WIRION by Gardia Medical) comprising an independent Filter Unit that can be delivered, locked, and deployed on any commercially marketed guide wire. Used by physicians during carotid and peripheral arterial catheter-based procedures.

3Needle-Stick Heart Valve Replacement Procedure
CategoryStructural heart / transcatheter valve replacement procedure
Description

First-in-human minimally invasive needle-stick procedure for replacing heart valves without open-heart surgery, performed on patients with severe heart failure caused by valve issues. Delivered rapid clinical improvements.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TruLeaf is a subsidiary of AllMeD Solutions developing the mitral valve regurgitation solution. The subsidiary has received Ethics Committee approval for human clinical trials in South Africa and R&D grant from Israel Innovation Authority. Phase I and Phase II human implantations have been performed.

Strategic tierMinorTypeOthers
Description

Acquired Allium Stents (fully covered diverse portfolio of urological stents) from AllMeD Solutions.

Strategic tierMinorTypeOthers
Description

Acquired Gardia Medical (embolic protection devices for carotid and peripheral arterial procedures) from AllMeD Solutions. CSI is now a subsidiary of Abbott, USA.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large incumbent with structural heart, peripheral intervention, and embolic protection (Watchman) franchises. Competes with AllMeD in embolic protection procedures and has been acquisitive in structural heart (e.g., bolt-on mitral investments).

TypeBroad incumbent
Description

Diversified medical device incumbent with a structural heart portfolio (Evolut TAVR, Intrepid TMVR). Comparable to AllMeD in targeting structural heart disease, though Medtronic operates at vastly greater scale across many other device categories.

TypeDirect peer
Description

Privately held developer of the Carillon Mitral Contour System, a transcatheter mitral annuloplasty device for functional mitral regurgitation. Direct peer to TruLeaf in targeting mitral regurgitation via minimally invasive, catheter-based approaches.

TypeDirect peer
Description

Global leader in structural heart therapies, including TAVR (sapien) and transcatheter mitral programs (PASCAL, Cardioband). Edwards is the most direct strategic competitor in mitral valve regurgitation treatment, the same condition TruLeaf is targeting.

TypeDirect peer
Description

Early-stage company developing the AltaValve transcatheter mitral valve system, designed for MR treatment without requiring native annular anchoring. Competes in the same mitral regurgitation treatment space as TruLeaf with a similar clinical-stage profile.

TypeDirect peer
Description

Clinical-stage developer of transcatheter aortic and mitral valve technologies, including transfemoral TAVR and AR treatment. Highly comparable in stage, focus area, and minimally invasive structural heart mission to AllMeD's TruLeaf division.

TypeDirect peer
Description

Developer of transcatheter mitral valve replacement (saturn) technology, targeting mitral regurgitation through a minimally invasive approach. Closely comparable in technology category, stage, and target indication to AllMeD's TruLeaf.

TypeEmerging player
Description

Commercial-stage company focused on embolic prevention and cerebral protection systems, including the CGuard carotid stent and the SwitchGuard neuroprotection system. Comparable to ProCatid in targeting embolic protection during catheter-based cardiovascular procedures.

9Abbott
TypeBroad incumbent
Description

Acquired Gardia Medical (AllMeD's former subsidiary) via Cardiovascular Systems, Inc., and operates a major structural heart and vascular franchise including Tendyne (TMVR) and embolic protection. Directly comparable to AllMeD's former and current product categories.

TypeDirect peer
Description

Developer of the Emboliner total embolic protection catheter for use during transcatheter aortic valve replacement and other structural heart procedures. Direct peer to AllMeD's ProCatid embolic protection system in the embolic protection device category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AllMeD Solutions

Minimally Invasive Medical Devicesalmd-solutions.com

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli medical device company developing minimally invasive cardiovascular and embolic protection products, with its core subsidiary True Leaf advancing a mitral valve regurgitation treatment through clinical trials.

What AllMeD Solutions does

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli publicly-traded medical device company founded in 2001 and headquartered in Or-Aqiva. The company develops, manufactures, and markets minimally invasive medical products internationally, sold directly to hospitals and healthcare institutions for use by physicians treating cardiovascular and urological conditions. Following the 2026 divestitures of Allium Stents (urological stents, sold to Dahlhausen, Germany) and Gardia Medical (embolic protection, sold to Abbott via Cardiovascular Systems, Inc.), the operating business is concentrated on the True Leaf subsidiary's mitral valve regurgitation program — a novel valve-in-docking-station architecture developed toward a first-in-human needle-stick heart valve replacement procedure — together with the retained ProCatid (formerly WIRION) distal embolic protection system, an independent filter unit deliverable on any commercially marketed guide wire. The company is funded through small public-market private placements (TASE), an Israel Innovation Authority R&D grant, and continues to advance TruLeaf through Phase I and II human clinical trials with Ethics Committee approvals in Israel and South Africa. It generates revenue predominantly through hardware sales of medical devices, though no current revenue figure is publicly disclosed in the input data.

AllMeD Solutions firmographics

Firmographics
Name
AllMeD Solutions
Legal name
AllMeD Solutions Ltd.
Website
https://almd-solutions.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli medical device company developing minimally invasive cardiovascular and embolic protection products, with its core subsidiary True Leaf advancing a mitral valve regurgitation treatment through clinical trials.
Ownership category
akta.pro rank

AllMeD Solutions industry classification

Industry
Product category
Minimally Invasive Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Minimally invasive medical devices
  • Cardiovascular intervention devices
  • Mitral valve repair systems
  • Embolic protection systems
  • Urological stents

Where AllMeD Solutions is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

AllMeD Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Manufacturing and Sales: AllMeD Solutions Ltd develops, manufactures and markets minimally invasive medical products internationally. Products are used by physicians to treat a wide range of diseases and patients worldwide.

Distribution channels1 record

Marketing channels3 records

AllMeD Solutions product offering

Product offering

Core offering

AllMeD Solutions Ltd. (TASE: ALMD) develops, manufactures, and markets minimally invasive medical products internationally. Its current portfolio centers on the TruLeaf division's mitral valve docking system for valve-in-docking-station implantation (in clinical trials) and the ProCatid distal embolic protection system — an independent filter unit compatible with any commercially marketed guide wire. Previously owned divisions Allium Stents (urological stents) and Gardia Medical (embolic protection devices) have been divested.

Product overview

AllMeD Solutions Ltd. is a publicly traded company (TASE: ALMD) that develops, manufactures and markets minimally invasive medical products internationally. The company's portfolio includes its core subsidiary TruLeaf, which focuses on mitral valve regurgitation solutions with a docking system for valve replacement, and the ProCatid System, a distal embolic protection system. Previously sold subsidiaries include Allium Stents (urological stents) and Gardia Medical (embolic protection devices). The company invests in minimally invasive interventions that improve patient recovery processes.

Differentiator

Problem solved

Functional benefit

Brands

  • True Leaf: Division developing solutions for mitral valve regurgitation treatment
  • ProCatid Medical

Products and services

  • TruLeaf Mitral Valve Docking System A minimally invasive mitral valve regurgitation solution consisting of a docking system that supports valve-in-docking-station implantation. Developed for patients with mitral valve regurgitation affecting millions of people worldwide. Phase I and Phase II human implantations have been performed by the True Leaf division.
  • ProCatid Distal Embolic Protection System A distal embolic protection system (formerly known as WIRION by Gardia Medical) comprising an independent Filter Unit that can be delivered, locked, and deployed on any commercially marketed guide wire. Used by physicians during carotid and peripheral arterial catheter-based procedures.
  • Needle-Stick Heart Valve Replacement Procedure First-in-human minimally invasive needle-stick procedure for replacing heart valves without open-heart surgery, performed on patients with severe heart failure caused by valve issues. Delivered rapid clinical improvements.

Quantifiable outcome

  • Rapid clinical improvements observed in patients with severe heart failure caused by valve issues following needle-stick procedure

Companies that use AllMeD Solutions

Customer profile

Segments3 records

Ideal customer profiles1 record

AllMeD Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AllMeD Solutions partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • TruLeaf MedicalcoreStrategic or Co-development PartnerTruLeaf is a subsidiary of AllMeD Solutions developing the mitral valve regurgitation solution. The subsidiary has received Ethics Committee approval for human clinical trials in South Africa and R&D grant from Israel Innovation Authority. Phase I and Phase II human implantations have been performed.
  • Dahlhausen Medical EquipmentminorOthersAcquired Allium Stents (fully covered diverse portfolio of urological stents) from AllMeD Solutions.
  • Cardiovascular Systems, Inc (CSI)minorOthersAcquired Gardia Medical (embolic protection devices for carotid and peripheral arterial procedures) from AllMeD Solutions. CSI is now a subsidiary of Abbott, USA.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

AllMeD Solutions competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Large incumbent with structural heart, peripheral intervention, and embolic protection (Watchman) franchises. Competes with AllMeD in embolic protection procedures and has been acquisitive in structural heart (e.g., bolt-on mitral investments).
  • Medtronic: Diversified medical device incumbent with a structural heart portfolio (Evolut TAVR, Intrepid TMVR). Comparable to AllMeD in targeting structural heart disease, though Medtronic operates at vastly greater scale across many other device categories.
  • Abbott: Acquired Gardia Medical (AllMeD's former subsidiary) via Cardiovascular Systems, Inc., and operates a major structural heart and vascular franchise including Tendyne (TMVR) and embolic protection. Directly comparable to AllMeD's former and current product categories.

Direct peers

  • Cardiac Dimensions: Privately held developer of the Carillon Mitral Contour System, a transcatheter mitral annuloplasty device for functional mitral regurgitation. Direct peer to TruLeaf in targeting mitral regurgitation via minimally invasive, catheter-based approaches.
  • Edwards Lifesciences: Global leader in structural heart therapies, including TAVR (sapien) and transcatheter mitral programs (PASCAL, Cardioband). Edwards is the most direct strategic competitor in mitral valve regurgitation treatment, the same condition TruLeaf is targeting.
  • 4C Medical Technologies: Early-stage company developing the AltaValve transcatheter mitral valve system, designed for MR treatment without requiring native annular anchoring. Competes in the same mitral regurgitation treatment space as TruLeaf with a similar clinical-stage profile.
  • JenaValve Technology: Clinical-stage developer of transcatheter aortic and mitral valve technologies, including transfemoral TAVR and AR treatment. Highly comparable in stage, focus area, and minimally invasive structural heart mission to AllMeD's TruLeaf division.
  • InnovHeart: Developer of transcatheter mitral valve replacement (saturn) technology, targeting mitral regurgitation through a minimally invasive approach. Closely comparable in technology category, stage, and target indication to AllMeD's TruLeaf.
  • Emboline: Developer of the Emboliner total embolic protection catheter for use during transcatheter aortic valve replacement and other structural heart procedures. Direct peer to AllMeD's ProCatid embolic protection system in the embolic protection device category.

Emerging players

  • InspireMD: Commercial-stage company focused on embolic prevention and cerebral protection systems, including the CGuard carotid stent and the SwitchGuard neuroprotection system. Comparable to ProCatid in targeting embolic protection during catheter-based cardiovascular procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

AllMeD Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AllMeD Solutions leadership team

Management profile

Number of profiles

Profiles1 record

AllMeD Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

AllMeD Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AllMeD Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllMeD Solutions

What does AllMeD Solutions do?

AllMeD Solutions Ltd. (TASE: ALMD) develops, manufactures, and markets minimally invasive medical products internationally. Its current portfolio centers on the TruLeaf division's mitral valve docking system for valve-in-docking-station implantation (in clinical trials) and the ProCatid distal embolic protection system — an independent filter unit compatible with any commercially marketed guide wire. Previously owned divisions Allium Stents (urological stents) and Gardia Medical (embolic protection devices) have been divested.

Is AllMeD Solutions a public or private company?

AllMeD Solutions is a public company. It is classified as public and is currently operating.

When was AllMeD Solutions founded?

AllMeD Solutions was founded in 2001. It employs 11 to 50 people.

Where is AllMeD Solutions based?

AllMeD Solutions is headquartered in Caesarea, Israel, in the Middle East region.

How does AllMeD Solutions make money?

One revenue line is on record: medical Device Manufacturing and Sales.

Who are AllMeD Solutions's main competitors?

Broad incumbents on record are Boston Scientific, Medtronic and Abbott. Direct peers are Cardiac Dimensions, Edwards Lifesciences, 4C Medical Technologies, JenaValve Technology, InnovHeart and Emboline. InspireMD is listed as an emerging player.

Does AllMeD Solutions have an API?

No public API is recorded for AllMeD Solutions.

What industry is AllMeD Solutions in?

AllMeD Solutions's product category is Minimally Invasive Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTruLeaf Medical, a fully-owned subsidiary of Allmed Solutions successfully Completed the Second Stage of valve implantation in two Additional PatientsTruLeaf Medical completed the second stage of percutaneous tricuspid valve implantation in two additional high-risk patients, with the first stage performed three months prior. The RoseDoc system shows exceptional safety and efficacy over nine-month follow-up, confirming its stability and long-term performance.PR NewswireAllmed Solutions Achieves Landmark 'Needle-Stick' Heart Valve ReplacementAllmed Solutions, an Israeli biomedical company, has achieved a breakthrough first-in-human trial success by performing full heart valve replacements via a minimally invasive catheterization procedure on two critically ill patients with severe tricuspid valve leakage, eliminating the need for high-risk open-chest surgery. The RoseDoc system, featuring a proprietary docking system, resulted in immediate clinical improvement for both patients who were discharged within five days, with the CEO calling it a defining moment in cardiac treatment. The company plans to expand trials to India, South Africa, and Uzbekistan as it advances toward global regulatory approval and commercialization.PR NewswireVote of confidence in TruLeaf Medical, subsidiary of AllMeD Solutions: 11.5 million NIS grant awarded by the Israel Innovation AuthorityThe Israel Innovation Authority approved an additional grant of approximately NIS 1.5 million to TruLeaf Medical, bringing the total funding received from the authority to NIS 11.5 million. This support validates the technological innovation of TruLeaf's minimally invasive transcatheter mitral valve replacement system, which aims to treat high-risk patients without open-heart surgery. The grant follows recent regulatory approval in Uzbekistan for human clinical trials of the device.PR NewswireAllMeD Solutions Reports Receipt of the Full Payment for PIPE Fundraising of Over $3.5 MillionAllMeD Solutions (TASE: ALMD) announced receipt of full payment for a PIPE fundraising round totaling over $3.5 million, completed at a 45% premium above the pre-transaction market share price. The fundraising was conducted amid challenging market conditions characterized by inflation and rising interest rates. The company stated the additional funds, combined with existing cash and expected considerations from prior strategic transactions, will enhance financial stability to support its subsidiaries and achieve its goals.